BioSpace News Archive

Neoleukin Therapeutics, Inc., “Neoleukin”, a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, announced three presentations at the upcoming American Association for Cancer Research Annual Meeting taking place April 8-13, 2022 in New Orleans, Louisiana.

Varex Imaging Corporation announced that it is scheduled to present at Oppenheimer’s 32nd Annual Healthcare virtual investor conference.

CytoSorbents Corporation reported audited financial and operating results for the quarter and year ended December 31, 2021 and provides its 2022 outlook.

Agiliti Inc., a nationwide provider of healthcare technology management and service solutions to the United States healthcare industry, announced its financial results for the fourth quarter and year ended December 31, 2021, and provides its financial outlook for 2022.

Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced that it will present four posters at the upcoming American Association for Cancer Research (AACR) Annual Meeting to be held April 8 to 13, 2022.

Surgalign Holdings, Inc., a global medical technology company focused on elevating the standard of care by driving the evolution of digital health, announced it plans to release financial results from the fourth quarter and full year 2021 after the close of trading on March 15, 2022.

Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology therapeutics that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems, today announced that it will present posters for three of the company’s preclinical pipeline programs at the upcoming American Association of Cancer Research (AACR) Annual Meeting 2022.

Nykode Therapeutics AS (Euronext Growth (Oslo): NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of vaccines and novel immunotherapies, today announced that preclinical data from its Vaccibody™ vaccine platform technology will be presented at the upcoming 2022 American Association for Cancer Research (AACR) Annual Meeting.

Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that two abstracts with clinical data of its innate cell engagers (ICE®) have been accepted for presentation at the annual meeting of the American Association for Cancer Research (AACR).

C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today announced that the Company will present a poster and three oral presentations at the American Association for Cancer Research (AACR) Annual Meeting 2022.